Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

LAIR-1 agonism as a therapy for acute myeloid leukemia.

Autor: Lovewell RR; NextCure Inc., Beltsville, Maryland, USA., Hong J; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Seoul National University Hospital and.; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea., Kundu S; NextCure Inc., Beltsville, Maryland, USA., Fielder CM; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Hu Q; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Kim KW; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Ramsey HE; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Gorska AE; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Fuller LS; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Tian L; NextCure Inc., Beltsville, Maryland, USA., Kothari P; NextCure Inc., Beltsville, Maryland, USA., Paucarmayta A; NextCure Inc., Beltsville, Maryland, USA., Mason EF; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center., Meza I; NextCure Inc., Beltsville, Maryland, USA., Manzanarez Y; NextCure Inc., Beltsville, Maryland, USA., Bosiacki J; NextCure Inc., Beltsville, Maryland, USA., Maloveste K; NextCure Inc., Beltsville, Maryland, USA., Mitchell N; NextCure Inc., Beltsville, Maryland, USA., Barbu EA; NextCure Inc., Beltsville, Maryland, USA., Morawski A; NextCure Inc., Beltsville, Maryland, USA., Maloveste S; NextCure Inc., Beltsville, Maryland, USA., Cusumano Z; NextCure Inc., Beltsville, Maryland, USA., Patel SJ; NextCure Inc., Beltsville, Maryland, USA., Savona MR; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Vanderbilt Center for Immunobiology.; Vanderbilt-Ingram Cancer Center, and.; Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA., Langermann S; NextCure Inc., Beltsville, Maryland, USA., Myint H; NextCure Inc., Beltsville, Maryland, USA., Flies DB; NextCure Inc., Beltsville, Maryland, USA., Kim TK; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center.; Vanderbilt Center for Immunobiology.; Vanderbilt-Ingram Cancer Center, and.; Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA.; Veterans Affairs Tennessee Valley Healthcare, Nashville, Tennessee, USA.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2023 Nov 15; Vol. 133 (22). Date of Electronic Publication: 2023 Nov 15.